Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of risk mitigation measures on oral fluoroquinolone prescribing: a multi-site population-based Canadian cohort study.

Archives of public health = Archives belges de sante publique·2026
Same author

Initial Treatment of COPD with LABA-LAMA Versus LAMA: Real-World Comparative Effectiveness and Safety.

COPD·2026
Same author

Short-Acting Beta-Agonists or No Short-Acting Beta-Agonists for Mild Asthma.

Chest·2026
Same author

Initial treatment of COPD with LABA-ICS or LABA-LAMA: real-world comparative effectiveness.

BMJ open respiratory research·2025
Same author

Response.

Chest·2025
Same author

Letter Reply to: Reassessing Gabapentinoids in Chronic Obstructive Pulmonary Disease: Emerging Respiratory Safety Concerns.

COPD·2025
Same journal

Obstructive sleep apnea syndrome and hypothyroidism - merely concurrence or causal association?

Pneumonologia i alergologia polska·2016
Same journal

The role of the TGF-SMAD signalling pathway in the etiopathogenesis of severe asthma.

Pneumonologia i alergologia polska·2016
Same journal

Hemoptysis in a patient with multifocal primary pulmonary angiosarcoma.

Pneumonologia i alergologia polska·2016
Same journal

Musculosceletal tuberculosis with involvement of tendon sheaths and formation of synovial cyst.

Pneumonologia i alergologia polska·2016
Same journal

The incidence of tuberculosis transmission among family members and outside households.

Pneumonologia i alergologia polska·2016
Same journal

Centrilobular nodules in high resolution computed tomography of the lung in IPAH patients - preliminary data concerning clinico-radiological correlates.

Pneumonologia i alergologia polska·2016
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

Mega trials in COPD--clinical data analysis and design issues.

Samy Suissa1, Pierre Ernst

  • 1Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Department of Epidemiology, McGill University, Montreal, Canada. samy.suissa@mcgill.ca

Pneumonologia I Alergologia Polska
|April 22, 2011
PubMed
Summary
This summary is machine-generated.

Long-acting bronchodilators, not inhaled corticosteroids, reduce mortality in COPD patients. Rigorous study design and analysis are crucial for accurate findings in large clinical trials like TORCH and UPLIFT.

More Related Videos

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Related Experiment Videos

Last Updated: Jun 2, 2026

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Area of Science:

  • Pulmonary Medicine
  • Clinical Trial Design
  • Pharmacotherapy

Background:

  • The TORCH and UPLIFT trials provided significant data on Chronic Obstructive Pulmonary Disease (COPD) treatments.
  • Lessons learned from these trials highlight areas for improvement in study design and data analysis.

Purpose of the Study:

  • To review the design and analysis of the TORCH and UPLIFT trials.
  • To critically evaluate the findings regarding COPD treatment efficacy and mortality benefits.
  • To emphasize the importance of scientific rigor in large-scale clinical research.

Main Methods:

  • Review of study design and data analysis from the TORCH and UPLIFT randomised controlled trials.
  • Analysis of the intent-to-treat principle application for mortality and lung function outcomes.
  • Re-analysis of the TORCH study data as a 2x2 factorial trial.

Main Results:

  • The placebo group in TORCH did not represent 'usual care', impacting the study's primary question.
  • Inconsistent application of the intent-to-treat principle for mortality versus lung function outcomes introduced bias.
  • A re-analysis indicated that salmeterol (a long-acting beta-agonist) accounted for mortality benefits, not fluticasone (an inhaled corticosteroid).

Conclusions:

  • Long-acting bronchodilators (anticholinergics and beta-agonists) are associated with reduced COPD patient mortality.
  • Inhaled corticosteroids do not appear to confer a mortality benefit in COPD patients.
  • Future large-scale COPD trials require utmost scientific rigor in design and analysis to ensure reliable results.